Alnylam Pharmaceuticals (ALNY) Return on Capital Employed (2010 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Return on Capital Employed came in at 26.09% in Q2 2026, up 3193.0% YoY from 0.79% in Q2 2025, and up 28.3% on a QoQ basis from 20.34% in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Return on Capital Employed (2010 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 17 years of Return on Capital Employed data on file, last reported at 26.09% in Q2 2026.
- Quarterly Return on Capital Employed rose 3193.0% year-over-year to 26.09% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 26.09% (up 3193.0% YoY) and the FY2025 annual result came in at 15.99%, up 2220.0% from the prior year.
- Return on Capital Employed grew to 26.09% in Q2 2026, from 20.34% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 26.09% in Q2 2026 to a low of 31.68% in Q2 2023.
- A 5-year average of 8.06% and a median of 6.3% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 3526 bps — and 2025, when it plunged 942 bps.
- Tracing ALNY's Return on Capital Employed over 5 years: stood at 28.31% in 2022, then jumped by 65 bps to 9.84% in 2023, then surged by 41 bps to 5.83% in 2024, then surged by 350 bps to 14.57% in 2025, then jumped by 79 bps to 26.09% in 2026.
- The last three Return on Capital Employed figures came in at 26.09% (Q2 2026), 20.34% (Q1 2026), and 14.57% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -36.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.09% |
| Mar 31, 2026 | 20.34% |
| Dec 31, 2025 | 14.57% |
| Sep 30, 2025 | 8.39% |
| Jun 30, 2025 | -5.83% |
| Mar 31, 2025 | -3.66% |
| Dec 31, 2024 | -5.83% |
| Sep 30, 2024 | -6.52% |
| Jun 30, 2024 | 3.59% |
| Mar 31, 2024 | -6.09% |
| Dec 31, 2023 | -9.84% |
| Sep 30, 2023 | -13.27% |
| Jun 30, 2023 | -31.68% |
| Mar 31, 2023 | -28.19% |
| Dec 31, 2022 | -28.31% |
| Sep 30, 2022 | -29.74% |
| Jun 30, 2022 | -26.23% |
| Mar 31, 2022 | -22.82% |
| Dec 31, 2021 | -24.76% |
| Sep 30, 2021 | -24.59% |